Our Take
Lilly is using a unilateral deadline to force compliance with data audits, but hospitals are escalating to federal regulators instead of capitulating—a sign the 340B program's enforcement rules remain contested and unsettled.
Why it matters
The 340B program allows hospitals to buy drugs at steep discounts for uninsured and low-income patients. If manufacturers can unilaterally demand data sharing and withhold discounts as leverage, the program's protections erode—and so does hospital margins on already-thin patient care margins.
Do this week
Hospital CFOs and compliance officers: document which Lilly products your facility uses under 340B and audit your own diversion controls this week so you can respond to Lilly's demand with evidence rather than defensiveness.
Eli Lilly's Monday ultimatum to select hospitals
Eli Lilly has issued a compliance deadline to hospitals participating in the 340B drug discount program. The company is demanding that select facilities provide data to prove they are not engaging in "double-dipping"—using 340B discounts on drugs that are then billed to insurers at full price rather than reserved for uninsured and low-income patients, per Healthcare Dive reporting.
Hospitals that refuse to share the requested data must comply by Monday or face consequences, though Lilly has not publicly specified what those consequences will be. The most likely outcome is restriction or loss of access to Lilly's 340B pricing.
Rather than comply individually, several hospital networks are urging the federal government to intervene. The Health Resources and Services Administration (HRSA) oversees the 340B program, and hospitals are signaling that Lilly's unilateral enforcement action exceeds the manufacturer's authority under the program's statutory framework.
The 340B program is already fragile
The 340B program has been a flashpoint between manufacturers and hospitals for years. Manufacturers argue hospitals abuse the discount by diverting drugs intended for safety-net populations to paying patients. Hospitals argue manufacturers are inventing diversion claims to justify price discrimination and margin recovery.
Lilly's move to issue unilateral data demands backed by a threat to revoke discounts shifts enforcement from HRSA (the statutory authority) to the manufacturer itself. If this tactic succeeds, other drug makers will follow. Hospitals lose negotiating leverage, and HRSA's regulatory authority becomes advisory rather than binding.
The 340B program was designed to stretch federal healthcare dollars by allowing safety-net hospitals to reinvest savings into care for uninsured patients. If manufacturers can withhold discounts based on their own audit demands, the program's economics collapse for the hospitals most dependent on it.
What hospital compliance teams should do now
If your hospital has received a data demand from Eli Lilly or anticipates one, do not wait for Monday's deadline to move. Audit your own 340B diversion controls first. Identify which Lilly products you purchase under 340B, trace their dispensing to safety-net patients versus billed claims, and document your control framework.
A clean internal audit gives you two options: respond to Lilly with evidence of compliance (and remove one pressure point), or respond to HRSA with evidence that you are following the program's rules and that Lilly's demand overreaches federal authority.
Do not assume the federal government will intervene by Monday. Escalate internally to your CFO and general counsel now so leadership understands the financial exposure if discounts are revoked mid-fiscal-year.